{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

Prague07

MSIF was in Prague from 8-14 October.
The first half of the week concerned the annual meeting between MSIF and representatives from MSIF member societies worldwide, and board meetings, social events and receptions filled the days before Prague07 on Wednesday 10th October.

read more

back to top

Jaroslav Zika
Country: Czech Republic
Occupation: Retired Engineer
Year of diagnosis: 1987
Type of MS: PPMS


"I realise I lost my job and mobility to MS, but on the other hand I have learned things I would otherwise never have found out"

English Italian Russian German Spanish French Czech

In vivo bioactivity of interferon beta in multiple sclerosis patients with neutralizing antibodies is titer dependent.

Some patients on Interferon therapy develop antibodies to the drug, which reduce its effect. This study quantifies the levels of antibody which prevents effective use of interferon, and this information can be used to guide treatment.

authors: Sominanda A, Hillert J, Fogdell-Hahn A.

source: J Neurol Neurosurg Psychiatry. 2007 Oct 2; [Epub ahead of print]

read more

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

This study investigates the incidence of similar antibodies to those described above, this time in association with the new generation drug Natalizumab. In a large cohort taken from 2 randomized control studies, 6% of patients developed antibodies. Therefore the presence of antibodies should be investigated in patients who respond poorly to the drug.

authors: Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

source: Neurology. 2007 Oct 2;69(14):1391-403. Epub 2007 Aug 29

read more

Fingolimod: a novel immunosuppressant for multiple sclerosis.

This study reviews the evidence for a new oral agent which is currently being trialled for treating MS: Fingolimod. It acts by reducing the number of circulating lymphocytes, and so suppresses the immune system. Adversely, it can affect the heart rhythm and suppress the production of white blood cells which fight infection.

authors: Brown BA, Kantesaria PP, McDevitt LM.

source: Ann Pharmacother. 2007 Oct;41(10):1660-8. Epub 2007 Sep 4

read more

back to top

UK: The Symptom Relief Research Initiative from the UK MS Society

The UK MS Society launched the Symptom Relief Research Initiative in October, aiming to raise £2.5million over the next three years to fund projects in this vital area. The society is already funding five projects, including Cognitive Behavioural Therapy (CBT) for early stage MS and a Group-based Fatigue Management Programme.

read more

New scanner method may replace MRI

A machine that can quickly assess the state of nerve fibres in the retina in only five minutes may offer a better way to measure the progression of multiple sclerosis than the MRI examinations now used.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.